Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_1

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

NCT01296555
completedphase_1

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

NCT02285179
completedphase_1

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

NCT01862081
completedphase_1

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

NCT01967966
completedphase_1

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

NCT01814709

Clinical Trials (5)

Showing 5 of 5 trials
NCT01296555Phase 1

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Terminated
NCT02285179Phase 1

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

Completed
NCT01862081Phase 1

A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Completed
NCT01967966Phase 1

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

Completed
NCT01814709Phase 1

A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5